| abstract |
The present invention relates to (S) -4-((S) -3-fluoro-3- (2- (5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) ethyl) pyrrolidine-1 -Yl) -3- (3- (2-methoxyethoxy) phenyl) butanoic acid (1: 1) citrate, a compound comprising such a compound, a pharmaceutical composition comprising such a compound, a disease requiring an α v β 6 integrin antagonist Or related to the use of such compounds in therapy including the treatment of pathologies, in particular idiopathic pulmonary fibrosis. |